Avsola®

Avsola (infliximab-axxq) is a biosimilar to Remicade, a widely-prescribed monoclonal antibody that helps the body’s immune system by targeting and destroying certain cells helping to protect healthy cells from damage. Specifically it is a tumor necrosis factor (TNF) blocker used for many chronic inflammatory conditions. Avsola was approved by the FDA in December, 2019 as a biosimilar to Remicade.

For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.

MANUFACTURER:

Amgen

CLASS:
Biologics (TNF blockers)
WHAT IT TREATS:
  • Crohn’s Disease
  • Ulcerative Colitis (UC)
  • Rheumatoid Arthritis (RA)
  • Ankylosing Spondylitis (AS)
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Plaque Psoriasis
PRESCRIBED BY:
  • Gastroenterologists
  • Rheumatologists
  • Dermatologists
HOW ADMINISTERED:
IV infusion
FREQUENCY:

Three times in the first six weeks, then every 8 weeks

Length of infusion:
About two hours